CollPlant Biotechnologies Ltd. Reports February 2025 Developments & Market Expansion

Here are the key insights extracted from the provided financial report (Form 6-K) for CollPlant Biotechnologies Ltd.:

1. Company Information:

• Name: CollPlant Biotechnologies Ltd.
• Address: 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
• Commission File Number: 001-38370.

2. Reporting Period:

• The report is for the month of February 2025.

3. Form Type:

• This document is a Form 6-K, which is a report of a foreign private issuer.

4. Registration Statements:

• The report incorporates information into the registrant’s Registration Statements on Form S-8 and Form F-3, referencing several specific file numbers for related documents.

5. Recent Developments:

• On February 24, 2025, the company issued a press release titled “CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia.” This indicates a strategic move to enhance its market presence in these regions.

6. Exhibits:

• The press release related to the expansion is attached as Exhibit 99.1.

7. Signatures:

• The report is signed by Eran Rotem, who serves as the Deputy CEO and Chief Financial Officer of CollPlant Biotechnologies Ltd., confirming the authenticity of the document.

Summary:

CollPlant Biotechnologies Ltd. reported recent developments regarding the expansion of its product distribution in Europe and Asia. This strategic move could potentially enhance the company's market reach and revenue streams. The report adheres to SEC filing requirements for foreign private issuers, ensuring compliance with regulatory standards.